Novosteo Inc.
Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone metastasis and infection. Scientific co-founders Stewart Low and Philip Low of Purdue University have created a proprietary chemistry approach to bone targeting and have discovered novel biologics that accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces.
HealthcareLifesciences
West Lafayette, IN
$1M-10M
Funding
11-50
Employees
Company Mission
Novosteo has designed a series of fracture-targeted drugs that concentrate a drug's healing power specifically at the fracture site, thereby greatly accelerating and improving the healing process.
Looking for a better job?
Discover the best career opportunities with the best company cultures for you.
Do you work at this company?
Connect your business to thousands of engaged professionals in your city and beyond.
